Bronchodilator reversibility in patients with severe asthma included in the GAN registry.
K. Milger-Kneidinger (Munich, Germany), D. Skowasch (Bonn, Germany), E. Hamelmann (Bielefeld, Germany), C. Mümmler (Munich, Germany), M. Idzko (Vienna, Germany), C. Taube (Essen, Germany), A. Holtdirk (Hamm, Germany), H. Timmerman (Hamburg, Germany), R. Buhl (Mainz, Germany), S. Korn (Heidelberg und Mainz, Germany)
Source: International Congress 2022 – Allergy and asthma: biomarkers, phenotypes and real-world evidence
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Milger-Kneidinger (Munich, Germany), D. Skowasch (Bonn, Germany), E. Hamelmann (Bielefeld, Germany), C. Mümmler (Munich, Germany), M. Idzko (Vienna, Germany), C. Taube (Essen, Germany), A. Holtdirk (Hamm, Germany), H. Timmerman (Hamburg, Germany), R. Buhl (Mainz, Germany), S. Korn (Heidelberg und Mainz, Germany). Bronchodilator reversibility in patients with severe asthma included in the GAN registry.. 1678
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|